More NewsRead More
AVEO Announces Dosing of First Patient in the Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma
May 26, 2016
AVEO Announces Closing of Private Placement and Amended Term Loan to Fund Pivotal TIVO-3 Trial and Combination PD-1 Trial of Tivozanib in Renal Cell Cancer
May 18, 2016
A Peek Into The Markets: U.S. Stock Futures Rise Ahead Of Empire State Manufacturing Index
August 15, 2016
AVEO Oncology Reports First Quarter 2016 Financial Results and Provides Business Update
May 10, 2016
AVEO Announces Filing of Provisional Patent Applications for AV-353, a Notch 3-Specific Inhibitor Antibody for PAH
May 02, 2016
BRIEF-Aveo Oncology Q2 loss per share $0.13
August 04, 2016
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here